West Pharmaceutical Services (WST) Non-Current Deferred Tax Liability (2009 - 2026)

West Pharmaceutical Services (WST) has reported Non-Current Deferred Tax Liability for 18 consecutive years, with $22.4 million the latest figure, recorded in Q2 2026.

• Quarterly Non-Current Deferred Tax Liability fell 2.61% year-over-year to $22.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $22.4 million (down 2.61% YoY) and the FY2025 annual result came in at $23.0 million, down 73.95% from the prior year.
• Non-Current Deferred Tax Liability declined to $22.4 million in Q2 2026 per WST's latest filing, from $22.7 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for WST reached as high as $88.3 million in Q4 2024 and fell as low as $1.2 million in Q2 2022.
• A 5-year average of $27.3 million and a median of $19.0 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability slumped 90.16% — and 2023, when it soared 1183.33%.
• Year by year, Non-Current Deferred Tax Liability stood at $79.4 million in 2022, then advanced by 7.3% to $85.2 million in 2023, then rose by 3.64% to $88.3 million in 2024, then plunged by 73.95% to $23.0 million in 2025, then fell by 2.61% to $22.4 million in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $22.4 million, $22.7 million, and $23.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.